PubRank

J Treleaven

Author PubWeight™ 89.38‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial. Lancet 2000 2.72
2 Responses to a clinical test of mechanical provocation of nerve tissue in whiplash associated disorder. Man Ther 2002 1.76
3 Does donor-recipient ABO incompatibility protect against relapse after allogeneic bone marrow transplantation in first remission acute myeloid leukemia? Bone Marrow Transplant 2002 1.49
4 Prevention of breast cancer with tamoxifen--an update on the Royal Marsden Hospital pilot programme. Eur J Cancer 1990 1.47
5 Peripheral blood stem cell transplantation may result in increased relapse of acute myeloid leukaemia due to reinfusion of a higher number of malignant cells. Bone Marrow Transplant 1995 1.45
6 Vaginal stenosis following allogeneic bone marrow transplantation for acute myeloid leukaemia. Bone Marrow Transplant 1999 1.45
7 Guidelines on the insertion and management of central venous access devices in adults. Int J Lab Hematol 2007 1.42
8 Identification of patients who may benefit from prophylactic immunotherapy after bone marrow transplantation for acute myeloid leukemia on the basis of lymphocyte recovery early after transplantation. Blood 1998 1.21
9 Additional chromosome abnormalities confer worse prognosis in acute promyelocytic leukaemia. Br J Haematol 1997 1.14
10 Long-term follow-up of relapsed acute leukemia treated with immunotherapy after allogeneic transplantation: the inseparability of graft-versus-host disease and graft-versus-leukemia, and the problem of extramedullary relapse. Leuk Lymphoma 1999 1.05
11 The role of autologous transplantation in patients with multiple myeloma aged 65 years and over. Bone Marrow Transplant 2000 1.04
12 Circulating lymphoma cells in patients with B & T non-Hodgkin's lymphoma detected by immunoglobulin and T-cell receptor gene rearrangement. Br J Cancer 1987 1.01
13 A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results. Br J Haematol 1998 0.99
14 Autologous bone marrow transplantation for childhood acute lymphoblastic leukaemia in second remission - long-term follow-up. Bone Marrow Transplant 2000 0.98
15 High activity Rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to bone. Br J Cancer 2002 0.98
16 Chronic graft versus host disease is associated with long-term risk for pneumococcal infections in recipients of bone marrow transplants. Blood 2000 0.95
17 Bone marrow transplantation for primary refractory acute leukaemia. Bone Marrow Transplant 1994 0.94
18 Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma. Bone Marrow Transplant 2002 0.93
19 Lumbar spine kinesthesia in patients with low back pain. J Orthop Sports Phys Ther 1999 0.93
20 Comparison of new patients with Bence-Jones, IgG and IgA myeloma receiving sequential therapy: the need to regard these immunologic subtypes as separate disease entities with specific prognostic criteria. Bone Marrow Transplant 2001 0.91
21 Magnetic microspheres and monoclonal antibodies for the depletion of neuroblastoma cells from bone marrow: experiences, improvements and observations. Br J Cancer 1986 0.90
22 Prophylactic defibrotide in allogeneic stem cell transplantation: minimal morbidity and zero mortality from veno-occlusive disease. Bone Marrow Transplant 2007 0.89
23 Central nervous system relapse after bone marrow transplantation for acute leukemia in first remission. Bone Marrow Transplant 1996 0.89
24 A low CD34+ cell dose results in higher mortality and poorer survival after blood or marrow stem cell transplantation from HLA-identical siblings: should 2 x 10(6) CD34+ cells/kg be considered the minimum threshold? Bone Marrow Transplant 2000 0.88
25 Paradoxical emboli after central venous catheter removal. Ann Oncol 2000 0.88
26 Cytokine profiles in stem cell transplantation: possible use as a predictor of graft-versus-host disease. Hematology 2005 0.88
27 Amphotericin B lipid complex (ABLC) for the treatment of confirmed or presumed fungal infections in immunocompromised patients with hematologic malignancies. Bone Marrow Transplant 1997 0.87
28 Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma. Br J Cancer 2000 0.87
29 Early identification of patients at risk of death due to infections, hemorrhage, or graft failure after allogeneic bone marrow transplantation on the basis of the leukocyte counts. Bone Marrow Transplant 1997 0.86
30 Manual examination: is pain provocation a major cue for spinal dysfunction? Aust J Physiother 2014 0.86
31 A phase 2 study of high-activity 186Re-HEDP with autologous peripheral blood stem cell transplant in progressive hormone-refractory prostate cancer metastatic to bone. Eur J Nucl Med Mol Imaging 2006 0.86
32 Parainfluenza type 3 infection post stem cell transplant: high prevalence but low mortality. J Hosp Infect 2006 0.85
33 A comparison of vincristine and doxorubicin infusional chemotherapy with methylprednisolone (VAMP) with the addition of weekly cyclophosphamide (C-VAMP) as induction treatment followed by autografting in previously untreated myeloma. Br J Haematol 1997 0.85
34 A toxic interaction between mitomycin C and tamoxifen causing the haemolytic uraemic syndrome. Eur J Cancer 1993 0.85
35 Outcome assessment of a population-based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment. Bone Marrow Transplant 1997 0.85
36 Quantification of residual disease in Philadelphia-positive acute lymphoblastic leukemia: comparison of blood and bone marrow. Leukemia 1995 0.84
37 An unusual presentation of acute myeloid leukaemia with pericardial and pleural effusions due to granulocytic sarcoma. Leuk Lymphoma 1993 0.84
38 Delayed engraftment associated with splenomegaly in patients undergoing bone marrow transplantation for chronic myeloid leukaemia. Bone Marrow Transplant 1990 0.84
39 Melphalan alone prior to allogeneic bone marrow transplantation from HLA-identical sibling donors for hematologic malignancies: alloengraftment with potential preservation of fertility in women. Bone Marrow Transplant 1996 0.84
40 Maintenance therapy for remission in myeloma with Intron A following high-dose melphalan and either an autologous bone marrow transplantation or peripheral stem cell rescue. Stem Cells 1995 0.83
41 An open, randomized, controlled, phase II, single centre, two-period cross-over study to compare the quality of life and toxicity experienced on PEG interferon with interferon-alpha2b in patients with multiple myeloma maintained on a steady dose of interferon-alpha2b. Ann Oncol 2007 0.83
42 Metastatic extramedullary plasmacytoma of the lung. Leuk Lymphoma 1999 0.83
43 Familial acute myeloid leukaemia: four male members of a single family over three consecutive generations exhibiting anticipation. Br J Haematol 1998 0.83
44 Use of physiological doses of human growth hormone in haematological patients receiving intensive chemotherapy promotes haematopoietic recovery: a double-blind randomized, placebo-controlled study. Bone Marrow Transplant 2006 0.82
45 Outcome of acute leukemia relapsing after bone marrow transplantation: utility of second transplants and adoptive immunotherapy. Bone Marrow Transplant 1997 0.82
46 Long-term safety of GM-CSF (molgramostim) administration after allogeneic bone marrow transplantation for hematologic malignancies: five-year follow-up of a double-blind randomized placebo-controlled study. Leuk Lymphoma 1997 0.82
47 Glomerular filtration rate prior to high-dose melphalan 200 mg/m(2) as a surrogate marker of outcome in patients with myeloma. Br J Cancer 2001 0.81
48 Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease. Bone Marrow Transplant 2003 0.81
49 Kinetics of paraprotein clearance after autografting for multiple myeloma. Bone Marrow Transplant 1995 0.81
50 Transfusion requirements after bone marrow transplantation from HLA-identical siblings: effects of donor-recipient ABO incompatibility. Bone Marrow Transplant 1996 0.81
51 Human recombinant GM-CSF in allogeneic bone-marrow transplantation for leukaemia: double-blind, placebo-controlled trial. Lancet 1990 0.81
52 Induction of graft-versus-host disease as immunotherapy of leukemia relapsing after allogeneic transplantation: single-center experience of 32 adult patients. Bone Marrow Transplant 1997 0.80
53 Allogeneic transplantation from HLA-matched sibling or partially HLA-mismatched related donors for primary refractory acute leukemia. Bone Marrow Transplant 2002 0.80
54 Treatment of relapsed and refractory acute leukaemia with high-dose cytosine arabinoside and etoposide. Cancer Chemother Pharmacol 1989 0.80
55 Cimetidine-induced myelosuppression after bone marrow transplantation. Leuk Lymphoma 1994 0.80
56 Extramedullary disease initially without bone marrow involvement in acute promyelocytic leukaemia. Clin Lab Haematol 1989 0.80
57 Unusual infections following allogeneic bone marrow transplantation for chronic lymphocytic leukemia. Bone Marrow Transplant 1994 0.80
58 Relationship between donor-recipient blood group incompatibility and serum bilirubin after allogeneic bone marrow transplantation from HLA-identical siblings. Bone Marrow Transplant 1995 0.80
59 Clinical and hematologic response of chronic lymphocytic and prolymphocytic leukemia persisting after allogeneic bone marrow transplantation with the onset of acute graft-versus-host disease: possible role of graft-versus-leukemia. Bone Marrow Transplant 1996 0.79
60 Comparison of interferon tolerance after autologous bone marrow or peripheral blood stem cell transplants for myeloma patients who have responded to induction therapy. Leuk Lymphoma 1996 0.79
61 Bone marrow transplantation--the Marsden experience. Hematol Oncol 1988 0.79
62 Renal dysfunction following autologous bone marrow transplantation in adult patients with acute leukemia. Acta Oncol 1996 0.79
63 Melphalan/TBI is not more carcinogeneic than cyclophosphamide/TBI for transplant conditioning: follow-up of 725 patients from a single centre over a period of 26 years. Bone Marrow Transplant 2000 0.79
64 High-dose melphalan and autotransplantation followed by post transplant maintenance chemotherapy for acute lymphoblastic leukemia in first remission. Bone Marrow Transplant 2004 0.78
65 Outcome of autologous rescue after failed engraftment of allogeneic marrow. Bone Marrow Transplant 1996 0.78
66 Long-term follow-up of patients undergoing allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission after cyclophosphamide-total body irradiation and cyclosporine. Bone Marrow Transplant 1996 0.78
67 Autologous bone marrow transplantation for acute myeloid leukemia in first remission: identification of modifiable prognostic factors. Bone Marrow Transplant 1995 0.78
68 An elective single autograft with high-dose melphalan: single-center study of 451 patients. Bone Marrow Transplant 2005 0.78
69 Evidence that multiple myeloma may be regulated by homeostatic control mechanisms: correlation of changes in the number of clonogenic myeloma cells in vitro with clinical response. Br J Cancer 1990 0.78
70 Paraplegia after intrathecal mitozantrone. Lancet 1986 0.78
71 Pilocarpine hydrochloride for symptomatic relief of xerostomia due to chronic graft-versus-host disease or total-body irradiation after bone-marrow transplantation for hematologic malignancies. Leuk Lymphoma 1997 0.78
72 Decrease in clonogenic tumour cells in bone marrow aspirates from multiple myeloma patients due to the incorporation of cyclophosphamide into treatment with vincristine, adriamycin and methyl prednisolone. Hematol Oncol 1991 0.78
73 Comparison of marrow and blood cell yields from the same donors in a double-blind, randomized study of allogeneic marrow vs blood stem cell transplantation. Bone Marrow Transplant 2000 0.78
74 Acute lymphoblastic leukaemia-type intensive chemotherapy to eliminate minimal residual disease after high-dose melphalan and autologous transplantation in multiple myeloma - a phase I/II feasibility and tolerance study of 17 patients. Bone Marrow Transplant 2000 0.78
75 Comparison of marrow vs blood-derived stem cells for autografting in previously untreated multiple myeloma. Br J Cancer 1997 0.78
76 The role of maintenance chemotherapy after autotransplantation for acute lymphoblastic leukemia in first remission: single-center experience of 100 patients. Bone Marrow Transplant 2008 0.78
77 Factors affecting engraftment and hematopoietic recovery after unpurged autografting in acute leukemia. Bone Marrow Transplant 1996 0.78
78 Three weeks of ganciclovir for cytomegaloviraemia after allogeneic bone marrow transplantation. Bone Marrow Transplant 1995 0.78
79 Listeriosis in bone marrow transplant recipients: incidence, clinical features, and treatment. Clin Infect Dis 1995 0.77
80 Mycophenolic acid trough level monitoring: relevance in acute and chronic graft versus host disease and its relation with albumin. Clin Transplant 2011 0.77
81 Oral idarubicin as a single agent therapy in patients with relapsed or resistant multiple myeloma. Leuk Lymphoma 1999 0.77
82 Complete remission rate and outcome after intensive treatment of 177 patients under 75 years of age with IgG myeloma defining a circumscribed disease entity with a new staging system. Br J Haematol 1999 0.77
83 Long-term outcome of adult acute leukemia patients who are alive and well two years after allogeneic bone marrow transplantation from an HLA-identical sibling. Leuk Lymphoma 1999 0.77
84 Collection of peripheral blood stem cells in newly diagnosed myeloma patients without any prior cytoreductive therapy: the first step towards an 'operational cure'? Bone Marrow Transplant 2002 0.77
85 Number of nucleated cells infused during allogeneic and autologous bone marrow transplantation: an important modifiable factor influencing outcome. Blood 1997 0.77
86 Results of a double blind placebo controlled study of ondansetron as an antiemetic during total body irradiation in patients undergoing bone marrow transplantation. Leuk Lymphoma 1992 0.76
87 Pressure pain thresholds of upper limb peripheral nerve trunks in asymptomatic subjects. Physiother Res Int 2000 0.76
88 A prospective comparison between magnetic resonance imaging, meta-iodobenzylguanidine scintigraphy and marrow histology/cytology in neuroblastoma. Eur J Cancer 1991 0.76
89 Male sexual function following bone marrow transplantation. Bone Marrow Transplant 1991 0.76
90 The feasibility of using topotecan, vinorelbine, thiotepa and gemcitabine (TVTG) in adult patients with relapsed/refractory acute lymphoblastic leukaemia/lymphoma. Leukemia 2008 0.76
91 Oral pilocarpine hydrochloride for the treatment of refractory xerostomia associated with chronic graft-versus-host disease. Blood 1995 0.76
92 The importance of CD34+/CD33- cells in platelet engraftment after intensive therapy for cancer patients given peripheral blood stem cell rescue. Bone Marrow Transplant 1998 0.76
93 Cytomegaloviremia after autografting for leukemia: clinical significance and lack of effect on engraftment. Leukemia 1997 0.76
94 The implication of compromised renal function at presentation in myeloma: similar outcome in patients who receive high-dose therapy: a single-center study of 251 previously untreated patients. Med Oncol 2001 0.76
95 Donor lymphocyte infusion for childhood acute lymphoblastic leukaemia relapsing after bone marrow transplantation. Br J Haematol 1997 0.76
96 Fatal pneumococcal infections following allogeneic bone marrow transplant. Bone Marrow Transplant 1994 0.76
97 Antimicrobial prophylaxis to prevent opportunistic infections in patients with chronic lymphocytic leukemia after allogeneic blood or marrow transplantation. Leuk Lymphoma 1997 0.76
98 Tumour lysis following hydrocortisone prior to a blood product transfusion in T-cell acute lymphoblastic leukaemia. Leuk Lymphoma 1992 0.76
99 High-dose cytosine arabinoside plus etoposide as initial treatment for acute myeloid leukaemia: a single centre study. Br J Cancer 1990 0.75
100 Leukocyte recovery and early treatment-related mortality after bone marrow transplantation. Blood 1997 0.75
101 Leukaemic relapse following Campath 1 treated bone marrow transplantation for leukaemia. Lancet 1986 0.75
102 Sequential development of myelodysplasia and acute myeloid leukemia but with no karyotypic evolution after autografting in a patient with Philadelphia positive acute lymphoblastic leukemia. Leuk Lymphoma 1997 0.75
103 Melphalan-total body irradiation and autologous bone marrow transplantation for adult acute leukemia beyond first remission. Bone Marrow Transplant 1996 0.75
104 Colony stimulating activity in the serum of patients with multiple myeloma is enhanced by interleukin 3: a possible role for interleukin 3 after high dose melphalan and autologous bone marrow transplantation for multiple myeloma. Br J Haematol 1990 0.75
105 Comparison of Cobe Spectra and Haemonetics MCS-3P cell separators for peripheral blood stem cell harvesting. Bone Marrow Transplant 1995 0.75
106 Sensitivity of secondary acute myeloid leukemia relapsing after allogeneic bone marrow transplantation to immunotherapy with interferon-alpha 2b. Bone Marrow Transplant 1997 0.75
107 Treatment of acute graft versus host disease with a murine monoclonal antibody to the IL-2 receptor. Bone Marrow Transplant 1991 0.75
108 Monoclonal antibodies and magnetic microspheres for the depletion of leukaemic cells from bone marrow harvested for autologous transplantation. Bone Marrow Transplant 1987 0.75
109 Colony-stimulating activity in the serum of patients with hemopoietic malignancies after intensive chemotherapy/radiotherapy: its augmentation by GM-CSF in vivo and interleukin 4 in vitro. Exp Hematol 1992 0.75
110 Red cell fragmentation (schistocytosis) after bone marrow transplantation. Bone Marrow Transplant 1998 0.75
111 Reassessing autotransplantation for acute myeloid leukaemia in first remission - a matched pair analysis of autologous marrow vs peripheral blood stem cells. Bone Marrow Transplant 2004 0.75
112 Feasibility and efficacy of maintenance chemotherapy following autologous bone marrow transplantation for first remission acute lymphoblastic leukaemia. Bone Marrow Transplant 1993 0.75
113 High-dose hydroxyurea and G-CSF to collect Philadelphia-negative cells in chronic myeloid leukemia: preliminary results. Leuk Lymphoma 1996 0.75
114 Idarubicin, high-dose cytarabine and etoposide for remission induction in therapy-related acute myeloid leukemia. Leuk Lymphoma 1994 0.75
115 Cyclosporine-induced graft-versus-host disease following autologous bone marrow transplantation in acute myeloid leukaemia. Bone Marrow Transplant 1990 0.75
116 No increase in relapse in patients with myeloid leukaemias receiving rhGM-CSF after allogeneic bone marrow transplantation. Bone Marrow Transplant 1992 0.75
117 How do allogeneic bone marrow transplants cure leukaemia? The role of graft versus host disease. Bone Marrow Transplant 1991 0.75
118 The impact of karyotype on remission rates in adult patients with de novo acute myeloid leukemia receiving high-dose cytarabine-based induction chemotherapy. Leuk Lymphoma 1999 0.75
119 Idarubicin, high-dose cytarabine, and etoposide for induction of remission in acute leukemia. Semin Hematol 1996 0.75
120 Autologous bone marrow and peripheral blood stem cell transplantation in haematological malignancies: current status. Med Oncol 1995 0.75
121 Human recombinant GM-CSF in allogeneic bone marrow transplantation for leukaemia: double-blind placebo controlled trial. Bone Marrow Transplant 1991 0.75
122 Leukaemic relapse after Campath 1 treated bone marrow transplantation for leukaemia. Lancet 1986 0.75
123 Oregon's civil commitment, statute: Stone's "thank-you theory" - a judicial survey. Bull Am Acad Psychiatry Law 1979 0.75
124 T cell-depleted allogeneic bone marrow transplantation from a partially HLA-mismatched unrelated donor for progressive chronic lymphocytic leukemia and fludarabine-induced bone marrow failure. Bone Marrow Transplant 1996 0.75
125 Prospective, concurrent comparison of the Cobe Spectra and Haemonetics MCS-3P cell separators for leukapheresis after high-dose filgrastim in patients with hematologic malignancies. J Clin Apher 1997 0.75
126 Allogeneic bone marrow transplantation for primary myelofibrosis. Bone Marrow Transplant 1995 0.75
127 Teaching cases from the Royal Marsden Hospital. Case 5: a child with fever, hepatosplenomegaly and cytopenia. Leuk Lymphoma 1992 0.75
128 Foscarnet therapy for cytomegalovirus infection after allogeneic bone marrow transplantation. Clin Infect Dis 1996 0.75
129 Haploidentical vs autologous hematopoietic stem cell transplantation in patients with acute leukemia beyond first remission. Bone Marrow Transplant 2003 0.75
130 Haemolytic uraemic syndrome in a patient with lung cancer: further evidence for a toxic interaction between mitomycin-C and tamoxifen. Clin Oncol (R Coll Radiol) 1996 0.75
131 Use of erythropoietin in the management of the haemolytic uraemic syndrome induced by mitomycin C/tamoxifen. Eur J Cancer 1994 0.75
132 Guillain-Barré syndrome after bone marrow transplantation. Bone Marrow Transplant 1994 0.75
133 Myelosuppressive chemotherapy to mobilize normal stem cells in chronic myeloid leukemia. Bone Marrow Transplant 1996 0.75
134 Cytokine-mediated immunotherapy with or without donor leukocytes for poor-risk acute myeloid leukemia relapsing after allogeneic bone marrow transplantation. Bone Marrow Transplant 1995 0.75
135 Phenoxyethanol is effective topical therapy of gram-negative cellulitis in neutropenic patients. J Hosp Infect 1993 0.75
136 Impact of cytogenetics on the outcome of autotransplantation for acute myeloid leukemia in first remission: is the benefit of intensive pretransplant therapy limited to patients with good karyotypes? Bone Marrow Transplant 2003 0.75
137 Autologous transplantation with CD52 monoclonal antibody-purged marrow for acute lymphoblastic leukemia: long-term follow-up. Leuk Lymphoma 1997 0.75
138 Bone-marrow transplant from father to son and subsequent graft from son to father. Lancet 1990 0.75
139 An adult with common acute lymphoblastic leukaemia (C-ALL) presenting with skin infiltration. Br J Dermatol 1991 0.75
140 Transplantation of autologous peripheral blood stem cells mobilized using GM-CSF for acute leukemia with myelofibrosis. Leuk Lymphoma 1993 0.75
141 Long-term outcome of adult acute leukemia patients who are alive and well 2 years after autologous blood or marrow transplantation. Bone Marrow Transplant 1999 0.75
142 Thrombocytopenia after bone marrow transplantation for leukaemia: changes in megakaryocyte growth and growth-promoting activity. Br J Haematol 1990 0.75
143 Graft failure after bone marrow transplantation from unrelated donors using busulphan and cyclophosphamide for conditioning. Bone Marrow Transplant 1994 0.75